Indication

Resectable Non-Small Cell Lung Cancer

1 clinical trial

1 product

1 drug

Clinical trial

Phase 2 Trial of Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab in Resectable Non-Small Cell Lung Cancer (Neo-KAN)

Status: Recruiting, Estimated PCD: 2025-11-01

Drug

Product

Adagrasib/Nivolumab